Biomarin Pharmaceutical Inc
BMRN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001048477
In the last 90 days, Biomarin Pharmaceutical Inc insiders filed 0 open-market purchases and 1 sale; 565 institutions reported holding it in 13F filings for Q2 2026, worth $11.1B in total; Viking Global Investors is the only superinvestor holding it.
Q3 2025 vs. Q2 2025
How the institutions holding Biomarin Pharmaceutical Inc changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Of which not filed for Q3 2025 | Q3 2025 | Change |
|---|---|---|---|---|
| Holders | 582 | 7 | 577 | +2 |
| Shares | 184.5M | 2.69M | 179.5M | −2.25M (−1.2%) |
| Value | $10.1B | $147.6M | $9.72B | −$271.6M (−2.7%) |
7 institutions that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (75)
Institutions that held Biomarin Pharmaceutical Inc at the end of Q3 2025 but not at the end of Q2 2025.
Sold out (73)
Institutions that held Biomarin Pharmaceutical Inc at the end of Q2 2025 and filed for Q3 2025 without it.
Not filed for Q3 2025 yet (7)
Institutions that held Biomarin Pharmaceutical Inc at the end of Q2 2025 and haven't filed a 13F for Q3 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Norges Bank | 2,043,879 | $112.4M |
| Camber Capital Management LP | 600,000 | $33.0M |
| E Fund Management Co., Ltd. | 18,772 | $1.03M |
| CIBC World Markets Corp | 7,985 | $438.9K |
| EP Wealth Advisors, LLC | 7,899 | $434.2K |
| Avantax Advisory Services, Inc. | 7,061 | $388.1K |
| Parkworth Wealth Management, Inc. | 2 | $110 |